What's Happening

Stay up to date on conferences, social posts, and what’s new with Healthesystems

Events

Let’s connect at one of our upcoming conferences or speaking engagements

MedMonitor

An up-to-date timeline of FDA approvals that could impact workers' comp
View All MedMonitor Information

Tryvio (aprocitentan) tablets

Approval Date: Mar 2024

Note: New Product

Indicated for the treatment of hypertension in combination with other antihypertensive drugs to lower blood pressure

hello world!

Simlandi® (adalimumab-ryvk) injection

Approval Date: Feb 2024

Note: Biosimilar

A biosimilar to Humira, this drug is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis, and plaque psoriasis

hello world!

Tybost (cobicistat) tablets

Approval Date: Feb 2024

Note: First-Time Generic

Indicated for the treatment of HIV-1 infection

hello world!

Dilaudid (hydromorphone hydrochloride) injection

Approval Date: Feb 2024

Note: First-Time Generic

Indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate

hello world!

Namzaric® (memantine and donepezil hydrochloride) extended release capsules

Approval Date: Dec 2023

Note: First-Time Generic

Indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily

hello world!

Zepbound (tirzepatide) injection

Approval Date: Nov 2023

Note: New Product

Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in obese adults, or overweight adults with at least one weight-related comorbidity

hello world!

Zituvimet (sitagliptin and metformin hydrochloride) tablets

Approval Date: Nov 2023

Note: New Product

Indicated as an adjunct to diet and exercise to improve glycemic control of type 2 diabetes

hello world!

Voquezna (vonoprazan fumarate) tablets

Approval Date: Nov 2023

Note: New Product

Indicated for erosive esophagitis and the relief of heartburn associated with erosive esophagitis

hello world!

Zymfentra (infliximab-dyyb) injection

Approval Date: Oct 2023

Note: New Product

Indicated for the maintenance treatment of moderate to severe ulcerative colitis or moderate to severe Crohn’s disease, following treatment with an infliximab product administered intravenously

hello world!

Omvoh (mirikizumab-mrkz) injection

Approval Date: Oct 2023

Note: New Product

A first-in-class agent indicated for the treatment of moderate to severe ulcerative colitis

hello world!

Social Hub

Check out our latest posts and activity
View All Social Media
    lockenvelopephone-handsetmagnifiermenucross-circle